DOD Ovarian Cancer Clinical Trial Award | W81XWH 22 OCRP CTA

Opportunity Information: Apply for W81XWH 22 OCRP CTA

The Department of Defense Ovarian Cancer Research Program (OCRP) Clinical Trial Award is a funding opportunity meant to speed up the launch and execution of clinical trials that could meaningfully improve how ovarian cancer is treated or managed. The emphasis is on moving quickly from a strong scientific rationale into a real-world clinical study, with the goal of generating evidence that can change clinical practice, guide future larger trials, or support the development of new standards of care. Trials supported under this award can cover a wide range of maturity levels, from early proof-of-concept work that tests feasibility and safety to larger studies designed to determine efficacy in the intended patient population.

This award is broad in what it will consider, as long as the work is firmly clinical-trial focused and directly relevant to ovarian cancer. Applicants can propose studies that evaluate new products or interventions, including pharmacologic agents such as drugs and biologics, medical devices, clinical guidance approaches (for example, new ways of delivering care or decision-making tools), and emerging technologies that could improve outcomes or patient management. The program is designed to accommodate different trial phases and purposes, including pilot studies, first-in-human efforts, and phase 0, phase 1, and phase 1/2 trials that may be used to demonstrate feasibility, refine protocols, identify early signals of activity, or generate key data needed to justify and design more definitive trials. At the same time, it can also support larger-scale clinical trials aimed at establishing efficacy, meaning it is not limited to early-stage testing if the proposed study is ready for broader evaluation.

Administratively, the opportunity is listed as "DOD Ovarian Cancer Clinical Trial Award" with Funding Opportunity Number W81XWH 22 OCRP CTA. It is offered by the Department of Defense, Department of the Army, through USAMRAA, and falls under CFDA number 12.420, categorized under science and technology and other research and development. The funding mechanism allows for either grants or cooperative agreements, which generally indicates that awards may range from more investigator-directed projects (grant) to projects that involve closer coordination or oversight with the sponsoring agency (cooperative agreement), depending on the specific award terms.

Eligibility is described as unrestricted, meaning it is open to any type of organization or entity, subject only to any additional eligibility details that may be spelled out in the full announcement text. The posting indicates an expected number of about four awards. The announcement was created on March 29, 2022, and the original closing date listed was August 5, 2022. The "award ceiling" field is shown as 0 in the provided data, which typically means the ceiling is not specified in that particular summary field and would normally be clarified in the full program announcement or related funding documents.

Overall, the core purpose of this opportunity is to fund well-justified ovarian cancer clinical trials that are ready to be implemented quickly and that have a clear line of sight to patient impact, whether that impact comes from demonstrating feasibility of a new approach, generating early clinical evidence to de-risk later studies, or producing definitive results that can inform treatment decisions in relevant ovarian cancer patient populations.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Ovarian Cancer Clinical Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 29, 2022.
• Applicants must submit their applications by Aug 05, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 OCRP CTA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: